Growth Hormone Secretagogues: Evidence and Safety
A review of CJC-1295, ipamorelin, and ibutamoren (MK-677), including the limits of GH-response studies and combination claims.
CJC-1295, ipamorelin, and MK-677 (ibutamoren) are grouped in “growth hormone stacks” because they affect growth hormone (GH) signaling through different targets. No controlled trial establishes that the three-compound combination improves recovery, muscle growth, sleep, or longevity. MK-677 is an orally active small molecule, not a peptide.
Distinguish a hormone signal from a patient benefit
A GH or IGF-1 increase is a biological measurement. It is not, by itself, evidence of a useful clinical outcome. GHRH and ghrelin-pathway interactions have been studied in small human physiology experiments, with results that depend on the agents and test conditions; they do not validate a CJC-1295/ipamorelin/MK-677 regimen. See the stacking evidence review.
| Compound | Research context | Key uncertainty |
|---|---|---|
| CJC-1295 | GH-secretagogue studies using particular formulations | Results do not define an approved general wellness protocol or establish equivalence between “DAC” and “no DAC” products. |
| Ipamorelin | GH-response research | FDA's compounding safety review describes safety concerns and limited data. |
| MK-677 | Human studies in selected populations, including an older-adult hip-fracture trial | Results in that population do not justify long-term use for healthy adults. FDA notes a separate trial stopped over a possible congestive-heart-failure signal. |
Safety questions
Changes in IGF-1, glucose tolerance, fluid retention, and other adverse effects need to be evaluated for each studied product and population. An increase in GH cannot be assumed to offset these risks. There are no validated “stack” targets, schedules, cycle lengths, or same-syringe compatibility data for these three compounds. In particular, a universal absolute IGF-1 threshold is not a safety rule; interpretation depends on age-adjusted laboratory ranges and the context of a specific medicine. See Peptide Blood Testing.
The FDA label for tesamorelin, an approved GHRH analog for a specific HIV-associated indication, illustrates that even a studied prescription product has defined warnings and monitoring. Its label cannot be applied wholesale to investigational secretagogues.
References
Stem-Cell Exhaustion and Intercellular Communication in Aging
Evidence guide to aging stem-cell niches, clonal hematopoiesis, cell signaling, young-plasma claims, exosomes, and regenerative peptide marketing.
Healing Peptide Combinations: What the Evidence Supports
An evidence review of BPC-157, TB-500, GHK-Cu, and thymosin alpha-1 for tissue repair, with limits of animal and human research.